Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2023: -7.27

Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities is -7.27 for the year ending December 31, 2023, a -18.63% change year over year. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow.
  • Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2022 was -6.13, a -2.47% change year over year.
  • Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2021 was -5.98, a -29.95% change year over year.
  • Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2020 was -4.60, a 28.04% change year over year.
  • Eliem Therapeutics Inc Operating Cash Flow To Current Liabilities for the year ending December 31, 2019 was -6.40.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email